Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment ...

There's nothing quite like the initial shock of thinning hair — an unnerving experience that makes us feel like our confidence is slipping away as fast as our strands. Hair is a big part of one's ...

Olumiant (baricitinib) is a prescription drug used to treat severe alopecia areata. It’s typically used when hair loss from this condition affects more than 50% of the scalp. Olumiant is a brand ...